Respiratory Medicine
Volume 97, Issue 1 , Pages 20-26 , January 2003

Cost–effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation

  • PW JONES

      Affiliations

    • St George's Hospital Medical School, London, U.K.
    • ,
  • K WILSON

      Affiliations

    • GlaxoSmithKline R&D, Greenford, Middlesex, U.K.
    • ,
  • S SONDHI

      Affiliations

    • GlaxoSmithKline R&D, Greenford, Middlesex, U.K.

Received 5 March 2002 ,Accepted 23 July 2002.

References 

    REFERENCES
  1. Am J Respir Crit Care Med. 1995;152:S77–S120
  2. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet. 1998;352:467–473
  3. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am. 1996;80:501–522
  4. Pelletier-Fleury N, Lanoe JL, Fleury B, Fardeau M. The cost of treating COPD patients with long term oxygen therapy in a French population. Chest. 1996;100:411–416
  5. Thom TJ. International comparisons in COPD mortality. Am Rev Respir Dis. 1989;140:S27–S34
  6. Donohue W, Plummer A. Magnitude and usage of home oxygen therapy in the United States. Chest. 1995;107:301–302
  7. Turner-Warwick M, Hudson ME, Corrin B. Clinical Atlas of Respiratory Diseases. London: Gower Medical Publishing; 1990;
  8. Mahler DA, Donahue JF, Barbee RA. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957–965
  9. Jones PW, Bosh T. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283–1289
  10. Boyd G, Morice AH, Pounsford JC. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997;10:815–821
  11. Jones PW, Quirck FH, Baveystock CM. The St. Respir Med. 1991;85:25–31
  12. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation — the St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327
  13. Desgagne A, Castilloux AM, Angers J-F, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. PharmacoEconomics. 1998;13:487–497
  14. Rutten-Van Molken MP, Van Doorslaer EK, Jansen MC. Cost and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975–982
  15. Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinaoate: an analysis of outcomes and cost–effectiveness using a primary care database. Resp Med. 1998;92:1302–1304
  16. Lorenzo G, Morici G, Drago A. Efficacy, tolerability and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther. 1998;20:1130–1148

PII: S0954-6111(02)91425-3

doi: 10.1053/rmed.2002.1425

Respiratory Medicine
Volume 97, Issue 1 , Pages 20-26 , January 2003

Article Tools